Viveve Medical, Inc. (VIVE): Price and Financial Metrics
VIVE Price/Volume Stats
|Current price||$0.04||52-week high||$1.20|
|Prev. close||$0.04||52-week low||$0.03|
|Day high||$0.07||Avg. volume||209,731|
|50-day MA||$0.05||Dividend yield||N/A|
|200-day MA||$0.37||Market Cap||428.96K|
VIVE Stock Price Chart Interactive Chart >
Viveve Medical, Inc. (VIVE) Company Bio
Viveve Medical, Inc. designs, develops, manufactures, and markets medical devices for the non-invasive treatment of vaginal laxity. The company was founded in 2005 and is based in Sunnyvale, California.
Most Popular Stories View All
VIVE Latest News Stream
|Loading, please wait...|
VIVE Latest Social Stream
View Full VIVE Social Stream
Latest VIVE News From Around the Web
Below are the latest news stories about VIVEVE MEDICAL INC that investors may wish to consider to help them evaluate VIVE as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We're starting off Tuesday with a look at the biggest pre-market stock movers that traders will want to keep an eye on today!
Viveve Announces Completion of Pivotal US PURSUIT Trial for Female Stress Urinary Incontinence with Final 12-month Follow-up Visits Concluded
Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and treatment of female stress urinary incontinence, today announced the completion of final 12-month post-treatment follow-up visits in its landmark U.S. PURSUIT clinical trial for the treatment of stress urinary incontinence (SUI) in women. A total of 415 patients were enrolled in the trial, and 342 patients completed 12-month follow-up visits.
Viveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary Incontinence
/ Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of female stress urinary incontinence (SUI), today announced the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11511110 covering Viveve's treatment to address SUI in women. The issuance of the new patent strengthens the Company's intellectual property portfolio in advance of the planned completion of its U.S.
Viveve Medical Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag
Viveve Medical ( NASDAQ:VIVE ) Third Quarter 2022 Results Key Financial Results Revenue: US$1.68m (up 4.2% from 3Q...
Viveve Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of female stress urinary incontinence (SUI), today reported financial results for the quarter ended September 30, 2022, and will provide a corporate update on its scheduled conference call at 5:00 PM ET today.
VIVE Price Returns
Continue Researching VIVEWant to see what other sources are saying about Viveve Medical Inc's financials and stock price? Try the links below:
Viveve Medical Inc (VIVE) Stock Price | Nasdaq
Viveve Medical Inc (VIVE) Stock Quote, History and News - Yahoo Finance
Viveve Medical Inc (VIVE) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...